Related references
Note: Only part of the references are listed.Soluble Receptor for Advanced Glycation End-products (sRAGE) and Colorectal Cancer Risk: A Case-Control Study Nested within a European Prospective Cohort
Elom K. Aglago et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2021)
AGE-RAGE synergy influences programmed cell death signaling to promote cancer
Bhargav N. Waghela et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2021)
Extracellular HMGB1 interacts with RAGE and promotes chemoresistance in acute leukemia cells
Weixin Lai et al.
CANCER CELL INTERNATIONAL (2021)
HMGB1 enhances chemotherapy resistance in multiple myeloma cells by activating the nuclear factor-κB pathway
Jing Ning et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2021)
Changes in Serum Interleukin-8 and sRAGE Levels in Multiple Myeloma Patients
Alessandro Allegra et al.
ANTICANCER RESEARCH (2020)
Longitudinal evaluation of Wnt inhibitors and comparison with others serum osteoimmunological biomarkers in osteolytic bone metastasis
Emanuela Galliera et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2020)
Dietary Advanced Glycation End-products (AGE) and Risk of Breast Cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO)
Omonefe O. Omofuma et al.
CANCER PREVENTION RESEARCH (2020)
Advanced glycation end products in diabetes, cancer and phytochemical therapy
Begum Dariya et al.
DRUG DISCOVERY TODAY (2020)
High mobility group box 1 (HMGB1): a pivotal regulator of hematopoietic malignancies
Shunling Yuan et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Interplay between RAGE and TLR4 Regulates HMGB1-Induced Inflammation by Promoting Cell Surface Expression of RAGE and TLR4
Hanhui Zhong et al.
JOURNAL OF IMMUNOLOGY (2020)
RAGE Signaling in Skeletal Biology
Lilian I. Plotkin et al.
CURRENT OSTEOPOROSIS REPORTS (2019)
HMGB1 modulates the balance between senescence and apoptosis in response to genotoxic stress
Je-Jung Lee et al.
FASEB JOURNAL (2019)
Evaluation of the AGE/sRAGE Axis in Patients with Multiple Myeloma
Alessandro Allegra et al.
ANTIOXIDANTS (2019)
Evaluation of thrombosis-related biomarkers before and after therapy in patients with multiple myeloma
Shosaku Nomura et al.
JOURNAL OF BLOOD MEDICINE (2018)
Targeting the Receptor for Advanced Glycation Endproducts (RAGE): A Medicinal Chemistry Perspective
Salvatore Bongarzone et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Advanced glycation endproducts (AGEs) in saliva of patients with multiple myeloma - a pilot study
Joseph Katz et al.
LEUKEMIA & LYMPHOMA (2017)
HMGB1 enhances the protumoral activities of M2 macrophages by a RAGE-dependent mechanism
Armando Rojas et al.
TUMOR BIOLOGY (2016)
Advanced glycation end products biphasically modulate bone resorption in osteoclast-like cells
Ziqing Li et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2016)
The Role of AGE/RAGE Signaling in Diabetes-Mediated Vascular Calcification
Amber M. Kay et al.
JOURNAL OF DIABETES RESEARCH (2016)
Impact of Oxidative Stress Biomarkers and Carboxymethyllysine (an Advanced Glycation End Product) on Prostate Cancer: A Prospective Study
Shuman Yang et al.
CLINICAL GENITOURINARY CANCER (2015)
Advanced Glycation End Products Affect Osteoblast Proliferation and Function by Modulating Autophagy Via the Receptor of Advanced Glycation End Products/Raf Protein/Mitogen-activated Protein Kinase/Extracellular Signalregulated Kinase Kinase/Extracellular Signal-regulated Kinase (RAGE/Raf/MEK/ERK) Pathway
Hong-Zheng Meng et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
HMGB1 Enhances Immune Suppression by Facilitating the Differentiation and Suppressive Activity of Myeloid-Derived Suppressor Cells
Katherine H. Parker et al.
CANCER RESEARCH (2014)
RAGE in tissue homeostasis, repair and regeneration
Guglielmo Sorci et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2013)
Soluble receptor for advanced glycation end products and risk of liver cancer
Kristin A. Moy et al.
HEPATOLOGY (2013)
Analysis of AGE modified proteins and RAGE expression in HER2/neu negative invasive ductal carcinoma
Arvind M. Korwar et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2012)
Increase of novel biomarkers for oxidative stress in patients with plasma cell disorders and in multiple myeloma patients with bone lesions
Sebastiano Gangemi et al.
INFLAMMATION RESEARCH (2012)
HMGB1 conveys immunosuppressive characteristics on regulatory and conventional T cells
Clarissa Anni Wild et al.
INTERNATIONAL IMMUNOLOGY (2012)
In situ accumulation of advanced glycation endproducts (AGEs) in bone matrix and its correlation with osteoclastic bone resorption
X. Neil Dong et al.
BONE (2011)
Evidence That Serum Levels of the Soluble Receptor for Advanced Glycation End Products Are Inversely Associated with Pancreatic Cancer Risk: A Prospective Study
Li Jiao et al.
CANCER RESEARCH (2011)
HMGB1 activates nuclear factor-κB signaling by RAGE and increases the production of TNF-α in human umbilical vein endothelial cells
Zheng-Gang Luan et al.
IMMUNOBIOLOGY (2010)
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
Lionel Apetoh et al.
NATURE MEDICINE (2007)
Non-enzymatic glycation of bone collagen modifies osteoclastic activity and differentiation
Ulrich Valcourt et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
The amphoterin (HMGB1)/receptor for advanced glycation end products (RAGE) pair modulates myoblast proliferation, apoptosis, adhesiveness, migration, and invasiveness - Functional inactivation of rage in L6 myoblasts results in tumor formation in vivo
F Riuzzi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Down-regulation of the receptor for advanced glycation end-products (RAGE) supports non-small cell lung carcinoma
B Bartling et al.
CARCINOGENESIS (2005)
The biology of the receptor for advanced glycation end products and its ligands
AM Schmidt et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2000)
Share Paper
